New eye treatment combo tested against standard therapy

NCT ID NCT07230184

Summary

This completed study tested whether adding a second drug (B55R2) to an existing treatment (B55R1) works better than using the single drug alone for diabetic retinopathy. Researchers followed 52 adults with non-proliferative diabetic retinopathy for 24 weeks, measuring changes in eye deposits and retinal thickness. The goal was to see if the combination therapy could better control this diabetes-related eye condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AJU Pharm Co., Ltd.

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.